Demand more. We do.
Sam Brown Inc. | Healthcare Communications
We understand. You are under pressure to deliver more value, meet higher standards. Shouldn’t you demand the same from your agency?
At Sam Brown Inc., we feel personally responsible for your success. We “get” healthcare – all players in all sectors. We custom tailor your team and strategies to fit your needs and achieve your specific goals.
And, we are obsessive about service. In short, we demand excellence from ourselves in everything we do. That’s how we’ve become a leading independent, full-service healthcare communications agency. And why some of the most respected companies in healthcare have been our clients for many years.
For the best teams, proven results and personalized service, talk to Sam Brown Inc.
Sam Brown Inc. is a full-service, independent healthcare communications agency offering:
• Corporate communications
• Public relations
• Financial communications
• Brand/marketing communications
• Creative services
• Media relations
• Social media communications
• Issues and crisis management
We serve all healthcare sectors with deep expertise in:
Pharmaceuticals, with experience in dozens of therapeutic areas
Biotechnology, from start-up to commercialization/private or public
Medical devices, diagnostics
Healthcare technology and healthcare services
Professional and patient associations
Patient assistance and access programs
For every new client, our first question is always the same: What do you want to accomplish? Attract investors? Increase interest in your clinical trials? Burnish your brand or reputation? Create patient and medical advocacy? Establish disease awareness? Increase share of voice?
>> Contact Us
at 484-380-2787 to talk about our experience in all of these areas of healthcare.
Whatever your goals, Sam Brown Inc. can help you reach them. We know how to engage with your target audiences, whether professionals, legislators, payors, caregivers, patients, government agencies or the general public. Our services span and integrate corporate communications; public, investor and media relations; creative services, and, of course, social media communications.
And everything we do is customized to fit your needs and your company like the finest tailored suit.
The right team. Spot-on strategies and tactics.
Relentless execution. Proven results.
Why We’re Different - Sam Brown Inc. has a unique business model. Based on your needs, we build customized, dedicated account teams from our nationwide network of senior healthcare communicators.
Our counselors view your goals and reputation as their personal challenges. All are consummate professionals (entrepreneurs, not employees) who take pride in their craft. They understand – it’s all about serving the clients and meeting their needs.
Our client-focused, service-oriented approach has been the key to our success since 1999. Here’s why Sam Brown has one of the highest client retention rates in our business.
In our business, client-agency relationships can be as brief as tsetse fly’s lifespan. When you work with Sam Brown Inc., you have a partner you can count on throughout your professional life.
We are exceptionally proud to be the agency for so many impressive pharmaceutical, biotechnology and healthcare companies. These include our founding clients DuPont, GlaxoSmithKline, Yamanouchi Pharmaceuticals and the Rohm and Haas Company.
But we are even prouder of the fact many of our client companies or client personnel have worked with us for more than ten years! A number of senior executives always take us with them when they start new companies.
Our commitment to client relationships has been the key to our success. But don’t take our word for it. Call our clients to see what they have to say about us and the work we’ve done for them.
Laura M. Liotta
Team Leader - Pharmaceutical Brand
Senior Communications Counselor
Media Relations Counselor
Research and Monitoring
With Sam Brown
Team Leader - Corporate Biotech
SVP and Strategy Leader
Team Leader - Healthcare Services
With Sam Brown
Senior Communications Counselor
With Sam Brown
West Coast Team Leader
With Sam Brown
Senior Communications Counselor
With Sam Brown
With Sam Brown
Senior Communications Counselor
With Sam Brown since 2002
Senior Communications Counselor
With Sam Brown since 2011
Alexis Van Saun
With Sam Brown
Achillion applies expertise in biology and structure-guided design and a deep understanding of patient, clinician, and payer needs to develop innovative treatment solutions aimed at improving patients’ lives. The company’s scientific excellence, integrated capabilities and experienced team position it to successfully advance new products along the entire continuum from the bench to the patient.
Alcobra Pharma is a publicly traded, emerging pharmaceutical company (NASDAQ – ADHD) primarily focused on the development and commercialization of our proprietary drug, METADOXINE EXTENDED RELEASE (MDX), to treat cognitive disorders including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome.
Blue Earth Diagnostics (BED) is a privately held diagnostics company focused on the development and commercialisation of molecular imaging technologies.
The Company’s lead product candidate is fluciclovine (18F) a PET imaging agent being developed for the detection and staging of cancer in prostate cancer patients experiencing a suspected recurrence of prostate cancer. BED filed for registration with both the Food & Drug Administration (FDA) and European Medicines Agency (EMA) in 2015.
For more than 50 years, BTG has been at the forefront of medical innovation. We
have helped to realise breakthroughs including Cephalosporin antibiotics, Interferon,
Magnetic Resonance Imaging, recombinant Factor IX, the first non-plasma product for
treating patients with haemophilia B, and abiraterone acetate, which has set a new
standard of care for treating men with advanced prostate cancer.
Today, we are a growing international specialist healthcare company that is dedicated
to improving the lives of people with cancer, vascular disorders and acute care needs. www.btgplc.com
Cidara Therapeutics is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. Our first product candidate is CD101 IV, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. Our second product candidate, CD101 topical, is a topical formulation of CD101, the first topical application of the enchinocandin class of antifungals, for the treatment of vulvovaginal candidiasis, or VVC.
Cipher Pharmaceuticals develops improved formulations of existing drugs. They search for products in defined markets to in-license into our pipeline. These products are based on currently marketed molecules paired with a novel drug delivery technology for enhanced performance. Their core competency is identifying these product opportunities and managing their clinical and regulatory development. Finally, they harvest the rewards by out-licensing to partners and generating royalty streams.
ControlRad Systems is a medical device company developing products that will dramatically reduce radiation dose and exposure while maintaining acceptable image quality, workflow, and utility of existing x-ray systems by delivering the right amount of radiation to the right spot at the right time. ControlRad products integrate incremental advances in several existing technologies, hence mitigating the technical risks. The novelty lies in the patented integration, the design of the incremental advances of each component part, and the software algorithms and programs that make the system operate as designed.
Cue Biopharma™ (Cue) is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. Cue biologics generate tailored immune responses in disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen presenting cells (APCs), and can potentially address any T cell-mediated disease. Through this platform approach, Cue has developed a portfolio of promising drug candidates with two lead programs currently approaching the clinic.
Eisai Inc. is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd, a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business.
Five Prime is a leader in the discovery and development of innovative protein therapeutics. They have developed a library of more than 5,700 human extracellular proteins, which we believe represent substantially all of the body’s medically important targets for protein therapeutics.
Building on this expertise in protein science, Five Prime has developed proprietary high-throughput protein screening technologies that they use to identify new targets for protein therapeutics in relatively short periods of time.
Galera Therapeutics is a privately held, clinical-stage biotech company discovering and developing innovative cancer treatments. Our development programs use precision targeting of oxygen metabolic pathways to offer novel therapeutics to improve both the tolerability of current anti-cancer treatments and directly treat cancer.
GlycoMimetics is a publicly traded, clinical-stage biotechnology company that utilizes novel and proprietary glycobiology technology to develop treatments for diseases, especially those with high unmet needs.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
HarborPath is a non-profit organization dedicated to helping uninsured living with HIV/AIDS and/or Hepatitis C gain access to free medications offered by Patient Assistance Programs (PAPs) by creating a single place for application and medication fulfillment. This "one stop shop" portal provides a streamlined, online process to qualify individuals and deliver the donated medications of the participating pharmaceutical companies through a mail-order pharmacy.
IDT Biologika is an innovative privately-held company with more than 90 years of experience in research, development, manufacture and distribution of biologics for the global protection of human and animal health. With the expertise and capacity to handle large-scale campaign production of human vaccines and biopharmaceuticals, IDT Biologika brings development, testing and regulatory excellence along with state-of-the-art manufacturing lines required to advance projects with the highest level of quality, efficiency and consistency of supply.
Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer).
Incyte Corporation is a biopharmaceutical company focused on discovering and developing proprietary, orally available drugs for serous unmet medical needs in oncology and inflammation. Incyte has a portfolio of novel compounds that have advanced into late-stage clinical development.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing, and commercializing meaningful products that address unmet medical needs.
Limelight Bio is developing novel gene therapies that greatly expand the utility of clinically-validated AAV vectors by enabling the treatment of diseases caused by large genes that exceed the payload capacity of AAV or by autosomal dominant inheritance patterns that cannot be addressed using traditional gene replacement approaches.
By leveraging fabrication techniques from the semiconductor industry, Liquidia has the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape, or composition. This unique ability to precisely engineer particles enables scientists to explore new product frontiers that, until now, have otherwise been out of reach. Using the Company’s proprietary PRINT® Platform, Liquidia is creating precisely engineered therapeutics and vaccines that address critical unmet patient needs.
Lupin Limited, headquartered in Mumbai, India, is strongly research focused. It has a program for developing New Chemical Entities. The company has a state-of-the-art R&D center in Pune and is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (ACE-inhibitors and cholesterol reducing agents) and has a notable presence in the areas of diabetes, anti-inflammatory and respiratory therapy.
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases.
MaxCyte was founded in 1999 to commercialize flow electroporation technology from the CBR Institute for Biomedical Research in Boston, Massachusetts. This technology was initially intended for the treatment of ischemic disorders with the initial clinical application of using flow electroporation to load 1 liter of an autologous red blood cell suspension with an alternative hemoglobin oxygen modulator. MaxCyte pursued the red blood cell application as well as investigated the use of the technology for loading a wide range of biologically active molecules into a variety of cell types.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease.
NephCure Kidney International ® is the only organization committed exclusively to support research seeking the cause of the potentially debilitating kidney disease Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome, improve treatment and find a cure.
NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.
The National Organization for Rare Disorders (NORD), a 501(c)(3) organization, is the leading voice of the rare disease community. NORD is a unique federation of voluntary health organizations dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them. For more than 30 years, NORD has been committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and service.
Numerate seeks to overcome major challenges in drug discovery by applying novel machine-learning algorithms, at cloud scale, to the problems of small-molecule drug design.
Peloton Therapeutics, Inc. is an oncology drug discovery and development company focused on advancing first-in-class small molecule therapies that provide patients suffering from life-threatening diseases with new therapeutic options. The company is driving forward multiple oncology programs targeting unexploited molecular vulnerabilities including adaptive processes that are induced in the tumor microenvironment by hypoxia, nutrient stress, and that result in evasion of anti-tumor immune responses.
Pulse Biosciences is a development-stage medical device company using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling or NPES.
NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. We believe that NPES can induce a variety of cellular responses including secretion, apoptosis and necrosis by modulating the NPES pulses, making it applicable to a wide variety of cell types and therapeutic applications.
Realm Therapeutics (AIM:RLM) is a biopharmaceutical company passionately committed to leveraging its proprietary immunomodulatory technology to protect and improve the health of adults and children.
In 2016, the Company began development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology.
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies for biologic drug discovery and mammalian Research Cell Banks for scale-up to manufacturing of recombinant therapeutic proteins. With the Company’s SUREtechnology Platform™ biopharmaceutical companies can significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for the production of monoclonal antibodies (MAbs) and other recombinant proteins including difficult-to-express proteins such as plasma proteins, GPCRs and non-natural proteins such as fusion proteins.
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of biology. Initially founded and incubated at Atlas Venture, we closed a $35 million Series A financing round in late 2014, led by Atlas Venture, Fidelity Biosciences, Lilly Ventures, and New Enterprise Associates (NEA). Also joining the Series A were Amgen Ventures, Novartis Institute for Biomedical Research (NIBR), and Elliott Sigal, MD, former head of R&D at BMS, who has also joined the company’s scientific advisory board (SAB).
Teleflex Medical is committed to solving the global challenges of the changing healthcare environment in the areas of critical care and surgical applications by providing products that are less invasive, reduce infections, and improve patient safety.
Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs such as the treatment of serious drug resistant and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics that provide a portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections, including broad-spectrum and selective-spectrum infections.
Therakos, Inc. is an immunotherapy company focused on providing innovative treatment platforms that harness the power of each individual patient’s immune system to fight disease. We are the global leader in autologous immune cell therapy delivered through extracorporeal photopheresis (ECP). www.therakos.com
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells to treat a wide range of disease indications. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing toward the clinic personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease.
Versartis, Inc. is an endocrine-focused biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders. The Company is initially developing somavaratan (VRS-317), its novel long-acting recombinant human growth hormone, for the treatment of pediatric growth hormone deficiency. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and yielding better treatment outcomes. The Company has recently initiated a Phase 3 clinical study of somavaratan in pediatric growth hormone deficient patients.
Vtesse, Inc. is a rare disease company dedicated to developing drugs for the unmet medical needs of patients suffering from severe and life-threatening diseases. Vtesse launched in 2015 to develop and seek regulatory approval for VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). They are working to conduct preclinical discovery and development of other novel drugs for NPC and other lysosomal storage diseases (LSDs). www.vtessepharma.com
17 - 41
© 2014 Sam Brown Inc. All Rights Reserved
Sam Brown Inc.
303 W. Lancaster Ave. #145 | Wayne, PA 19087
Don’t settle. Demand more from your communications agency.
Contact Laura Liotta at 484-380-2787.